The derivation process covered by the patent offers a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
Advanced Cell Technology president and chief executive officer Paul Wotton said the addition of this new patent continues to strengthen the company’s IP position around core cell therapy components and helps protect its leading position in the regenerative medicine field.
"It is an exciting time to be here as we concentrate our efforts on developing cures for diseases and disorders of the eye and get ready to initiate phase 2 clinical trials for the treatment of Stargardt’s macular degeneration (SMD) and age-related macular degeneration (AMD)."
ACT is focused on the development and commercialization of regenerative medicine and cell therapy technology, and its most advanced products are in clinical trials indicated to treat dry age-related macular degeneration, SMD and myopic macular degeneration.
The company’s preclinical programs include cell therapies to treat other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.